CompletedNo phase
Ablation at Virtual-hEart pRedicted Targets for VT
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 10 people enrolled
- Started
- 26 Sept 2022
- Ended
- 1 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Virtual Heart Guided Ablation
- Record updated
- 5 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Eligible patients must be at least 18 years old at the time of enrollment
- A Pre-Op cardiac MRI including late gadolinium enhancement (LGE) must be performed prior to ablation. As Johns Hopkins University (JHU) performs MRIs with implantable cardioverter defibrillator (ICD) or pacemaker implanted, patients with these devices may be enrolled
- Eligible patients must suffer from VT, thought to be secondary to structural heart disease (scarring)
- Eligible patients must be determined to be suitable candidates for ablation to treat VT by their cardiologist and/or electrophysiologists regardless of this protocol
Who cannot take part
- Patients with Glomerular Filtration Rate (GFR) < 30 mL/min should not be enrolled in the study due to the use of intravenous gadolinium as an MRI contrast agent
- If a pre-procedure MRI cannot or likely will not be performed for any reason (such as claustrophobia), the patient must be excluded
- Pregnant women may not participate in the study because gadolinium MRI contrast is contraindicated in these patients
- Any subject that, during the course of the pre-procedure imaging, is discovered to have VT not related to scarring, he/she must be de-enrolled from the study
Where in United States
- Johns HopkinsBaltimore, United StatesNo longer taking part
About the trial
What the trial wants to find out
The goal of this study is to test the efficacy of the new imaging/simulation ("virtual heart") approach for determining the optimal ablation sites in patients with VT, which render post-infarction VT non-inducible. The study will test both the acute outcome of the ablation procedure, and the effect the use of the predicted targets has upon procedure time.
The group in the trial
- Virtual Heart Guided AblationTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 5 February 2026